OverviewSuggest Edit

Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. It develops therapeutics that modulate lymphocyte activation gene-3, a cell surface molecule that plays a role in regulating T cells.
TypePublic
Founded2001
HQSydney, AU
Websiteimmutep.com

Latest Updates

Employees (est.) (Jun 2019)24(-27%)
Share Price (Nov 2020)$2 (-5%)
Cybersecurity ratingAMore

Key People/Management at Immutep

Marc Voigt

Marc Voigt

Executive Director & Chief Executive Officer (CEO)
Deanne Miller

Deanne Miller

Chief Operating Officer, General Counsel & Company Secretary
Christian Mueller

Christian Mueller

Director Clinical Development and Regulatory Affairs
James Flinn

James Flinn

Intellectual Property and Innovation Director
Michael Buchholz

Michael Buchholz

Director of Manufacturing
David Fang

David Fang

Finance Director & Assistant Company Secretary
Show more

Immutep Office Locations

Immutep has offices in Sydney, Orsay, Berlin and Leipzig
Sydney, AU (HQ)
level 12/95 Pitt St
Sydney, AU
level 12/225 George St
Orsay, FR
2 Rue Jean Rostand
Berlin, DE
Glinkastraße 28
Leipzig, DE
Deutscher Pl. 5A
Show all (5)

Immutep Financials and Metrics

Immutep Revenue

Market capitalization (16-Nov-2020)

97.7m

Closing stock price (16-Nov-2020)

2.0
Immutep's current market capitalization is $97.7 m.
Show all financial metrics

Immutep Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Immutep Online and Social Media Presence

Embed Graph

Immutep News and Updates

Immutep Announces Australian Patent Grant For IMP701 Antibody

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 2015229103 entitled “Antibody molecules to LAG-3 and uses thereof” by the Australian Patent Office.

Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that it has entered into a Licence and Collaboration Agreement with LabCorp tha…

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

SYDNEY, Australia, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the University Hospital Pilsen, Czech Republic to enable an investigator-initiated rando…

Immutep Activities Report for the First Quarter of Fiscal Year 2021

SYDNEY, Australia, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today provided a business update for the quarter ended September 30, 2020, including for the ongoing d…

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that interim Overall Survival (OS) results from it…

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. The data was presented in two poster presentations at the ESMO Virtual Congress 2020 on 17 September 2020 and relates to the cut-off …
Show more

Immutep Frequently Asked Questions

  • When was Immutep founded?

    Immutep was founded in 2001.

  • Who are Immutep key executives?

    Immutep's key executives are Marc Voigt, Deanne Miller and Christian Mueller.

  • How many employees does Immutep have?

    Immutep has 24 employees.

  • Who are Immutep competitors?

    Competitors of Immutep include OncoQuest, Calidi Biotherapeutics and IDP Pharma.

  • Where is Immutep headquarters?

    Immutep headquarters is located at level 12/95 Pitt St, Sydney.

  • Where are Immutep offices?

    Immutep has offices in Sydney, Orsay, Berlin and Leipzig.

  • How many offices does Immutep have?

    Immutep has 5 offices.